[go: up one dir, main page]

CA2245165A1 - Sensibilisation aux substances chimiotherapeutiques des cellules cancereuses surexprimant her2/neu - Google Patents

Sensibilisation aux substances chimiotherapeutiques des cellules cancereuses surexprimant her2/neu Download PDF

Info

Publication number
CA2245165A1
CA2245165A1 CA002245165A CA2245165A CA2245165A1 CA 2245165 A1 CA2245165 A1 CA 2245165A1 CA 002245165 A CA002245165 A CA 002245165A CA 2245165 A CA2245165 A CA 2245165A CA 2245165 A1 CA2245165 A1 CA 2245165A1
Authority
CA
Canada
Prior art keywords
emodin
tyrosine kinase
cells
neu
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002245165A
Other languages
English (en)
Inventor
Mien-Chie Hung
Lisha Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2245165A1 publication Critical patent/CA2245165A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Méthodes d'inhibition du produit génétique du neu oncogène p185neu tyrosine kinase. La surexpression du neu oncogène conduit à la chimiorésistance. Les méthodes présentées reposent sur l'utilisation nouvelle de l'émodine en association avec des substances chimiothérapeutiques servant à traiter le carcinome. En outre, l'émodine renforce les effets antinéoplasiques des agents chimiothérapeutiques, ce qui n'était pas connu. Selon l'invention, l'émodine sensibilise les cellules cancéreuses pour les rendre sensibles aux traitements par les substances chimiothérapeutiques.
CA002245165A 1996-01-31 1997-01-31 Sensibilisation aux substances chimiotherapeutiques des cellules cancereuses surexprimant her2/neu Abandoned CA2245165A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1087596P 1996-01-31 1996-01-31
US60/010,875 1996-01-31

Publications (1)

Publication Number Publication Date
CA2245165A1 true CA2245165A1 (fr) 1997-08-07

Family

ID=21747830

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002245165A Abandoned CA2245165A1 (fr) 1996-01-31 1997-01-31 Sensibilisation aux substances chimiotherapeutiques des cellules cancereuses surexprimant her2/neu

Country Status (5)

Country Link
EP (1) EP0877608A1 (fr)
JP (1) JP2000504020A (fr)
AU (1) AU1854597A (fr)
CA (1) CA2245165A1 (fr)
WO (1) WO1997027848A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326356B1 (en) 1996-10-18 2001-12-04 Board Of Regents, The University Of Texas System Suppression of neu overexpression using a mini-E1A gene
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
EP1027045A4 (fr) * 1997-10-31 2004-12-08 Arch Dev Corp Procedes et compositions pour reguler l'activite de la 5-alpha-reductase
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
HU231064B1 (hu) 1999-08-27 2020-03-30 Genentech, Inc. Anti-ErbB2 antitestek adagolási sémái és alkalmazásuk rákos betegségek kezelésére
US20040116330A1 (en) * 2001-04-27 2004-06-17 Kenichiro Naito Preventive/therapeutic method for cancer
US20040138160A1 (en) * 2001-04-27 2004-07-15 Kenichiro Naito Preventive/therapeutic method for cancer
EP2003966A4 (fr) 2006-04-07 2010-07-07 Sunten Phytotech Co Ltd Composés d'anthracènedione
WO2007132784A1 (fr) * 2006-05-15 2007-11-22 Niigata University Médicament antipsychotique et remède pour une anomalie cognitive contenant un dérivé de l'anthraquinone en tant que matière active
CN102099025A (zh) * 2008-05-16 2011-06-15 马尔药品公司 Pm00104与另一抗肿瘤剂的联合疗法
US8541382B2 (en) * 2010-11-13 2013-09-24 Sirbal Ltd. Cardiac glycoside analogs in combination with emodin for cancer therapy
RU2693004C1 (ru) * 2019-03-15 2019-07-01 Лейсан Фаридовна Минигулова Противоопухолевая композиция цисплатина с ингибитором 6-фосфоглюконатдегидрогеназы

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966918A (en) * 1989-01-27 1990-10-30 Sloan-Kettering Institute For Cancer Research Derivatives of chryosphanol
US5436243A (en) * 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance

Also Published As

Publication number Publication date
WO1997027848A1 (fr) 1997-08-07
EP0877608A1 (fr) 1998-11-18
AU1854597A (en) 1997-08-22
JP2000504020A (ja) 2000-04-04

Similar Documents

Publication Publication Date Title
Hotte et al. Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study
Ardizzoni et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.
Lu et al. Celastrol, a novel HSP90 inhibitor, depletes Bcr–Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation
Sun et al. The protective role of hydrogen-rich saline in experimental liver injury in mice
Flaig et al. A study of high‐dose oral silybin‐phytosome followed by prostatectomy in patients with localized prostate cancer
AU735884B2 (en) Treatment of carcinomas using squalamine in combination with other anti-cancer agents
Cascinu et al. Phase II study of paclitaxel in pretreated advanced gastric cancer
USRE45105E1 (en) Method of treating cancer by co-administration of anticancer agents
CA2245165A1 (fr) Sensibilisation aux substances chimiotherapeutiques des cellules cancereuses surexprimant her2/neu
Jin et al. Propofol limits rat myocardial ischemia and reperfusion injury with an associated reduction in apoptotic cell death in vivo
US20050043224A1 (en) Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
WO1997027848A9 (fr) SENSIBILISATION AUX SUBSTANCES CHIMIOTHERAPEUTIQUES DES CELLULES CANCEREUSES SUREXPRIMANT HER2/neu
De Jong et al. Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin
US20100203110A1 (en) Therapeutics for Cancer Using 3-Bromopyruvate and Other Selective Inhibitors of ATP Production
Jiang et al. Cimetidine induces apoptosis in gastric cancer cells in vitro and inhibits tumor growth in vivo
KR20180111077A (ko) 아스피린 및 다중 키나아제 억제제를 포함하는 항암제 내성 치료용 조성물
Mackenzie et al. A novel Ras inhibitor (MDC-1016) reduces human pancreatic tumor growth in mice
Taylor et al. Combination chemotherapy with cyclophosphamide, vincristine, adriamycin, and dexamethasone (CVAD) plus oral quinine and verapamil in patients with advanced breast cancer
Cheng et al. A novel small molecule inhibits tumor growth and synergizes effects of enzalutamide on prostate cancer
Guan et al. Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis
WO2020234454A1 (fr) Traitement combiné contre le cancer ciblant le métabolisme énergétique et le ph intracellulaire
Ji et al. Synergistic effect of honokiol and 5‐fluorouracil on apoptosis of oral squamous cell carcinoma cells
CA2525589A1 (fr) Traitement du cancer du pancreas
Wolfson et al. Enhancing FTS (Salirasib) efficiency via combinatorial treatment
Caraglia et al. Chemotherapy regimen GOLF induces apoptosis in colon cancer cells through multi-chaperone complex inactivation and increased Raf-1 ubiquitin-dependent degradation

Legal Events

Date Code Title Description
FZDE Dead